Background Anti-C1q autoantibodies can disrupt normal complement function, contributing to the formation of pathogenic immune ...
Background Lupus nephritis (LN) is the most serious complication of SLE. Interstitial fibrosis is the dominant pathological ...
Objective Small fibre neuropathy (SFN) is an under-recognised complication of SLE that contributes to chronic pain and ...
Objective Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that ...
Haematologic involvement in patients with systemic lupus erythematosus (SLE) is very common. The principal cytopenias in lupus result in anaemia, white cell deficits and thrombocytopenia. Anaemia may ...
The 2025 EULAR recommendations for the management of systemic lupus erythematosus (SLE) with kidney involvement followed the EULAR standardized operating procedures, by recruiting an international ...
Malignancy risk in systemic lupus erythematosus (SLE) is about 15% higher than the general age-and-sex-matched population. Hematologic cancers, especially B-cell lymphomas, are about three-fold ...
Background Povetacicept (ALPN-303) is an Fc fusion protein of a variant, engineered TACI domain, which mediates significantly more potent inhibitory activity than WT TACI-Fc or BAFF- or APRIL-specific ...
Background Each lupus nephritis (LN) flare causes nephron loss that equals a decade or more of reduction in renal function lifespan. Identification of readily available signals of imminent flare is ...
Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...
Systemic lupus erythematosus (SLE) is associated with a wide variety of ocular manifestations. Some of these include uveitis, occlusive retinal vasculitis, (epi)scleritis and keratitis. Uveitis is an ...
Hemophagocytic lymphohistiocytosis (HLH) is a well-recognised complication of systemic lupus erythematosus (SLE). In one small case series, HLH was noted in approximately 5% of patients with lupus. 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback